FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309268869> ?p ?o ?g. }

• W4309268869 endingPage "e063037" @default.
• W4309268869 startingPage "e063037" @default.
• W4309268869 abstract "Introduction Multiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly diagnosed cancers. At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, standard-risk patients, with detectable disease (minimal residual disease (MRD)-positive) postautologus stem cell transplant (ASCT), fare worse compared with those who do not (MRD-negative). Research is required to determine whether a risk-adapted approach post-ASCT could further improve patient outcomes. Methods RADAR is a UK, multicentre, risk-adapted, response-guided, open-label, randomised controlled trial for transplant-eligible newly diagnosed multiple myeloma patients, using combinations of lenalidomide (R), cyclophosphamide (Cy), bortezomib (Bor), dexamethasone (D) and isatuximab (Isa). Participants receive RCyBorD(x4) induction therapy, followed by high-dose melphalan and ASCT. Post-ASCT, there are three pathways as follows: A phase III discontinuation design to assess de-escalating therapy in standard-risk MRD-negative patients. Participants receive 12 cycles of Isa maintenance. Those who remain MRD-negative are randomised to either continue or stop treatment. A phase II/III multiarm multistage design to test treatment strategies for treatment escalation in standard-risk MRD-positive patients. Participants are randomised to either; R, RBorD(x4) +R, RIsa, or RBorIsaD(x4) + RIsa. A phase II design to assess the activity of intensive treatment strategies in high-risk patients. Participants are randomised to RBorD(x4) +R or RBorIsaD(x4) + RIsa. 1400 participants will be registered to allow for 500, 450 and 172 participants in each pathway. Randomisations are equal and treatment is given until disease progression or intolerance. Ethics and dissemination Ethical approval was granted by the London–Central Research Ethics Committee (20/LO/0238) and capacity and capability confirmed by the appropriate local research and development department for each participating centre prior to opening recruitment. Participant informed consent is required before trial registration and reconfirmed post-ASCT. Results will be disseminated by conference presentations and peer-reviewed publications. Trial registration number ISCRTN46841867." @default.
• W4309268869 created "2022-11-25" @default.
• W4309268869 creator A5001499861 @default.
• W4309268869 creator A5006399379 @default.
• W4309268869 creator A5012617779 @default.
• W4309268869 creator A5015764509 @default.
• W4309268869 creator A5022440254 @default.
• W4309268869 creator A5023678967 @default.
• W4309268869 creator A5024897723 @default.
• W4309268869 creator A5026876598 @default.
• W4309268869 creator A5033896752 @default.
• W4309268869 creator A5036826164 @default.
• W4309268869 creator A5038580329 @default.
• W4309268869 creator A5040293585 @default.
• W4309268869 creator A5042419236 @default.
• W4309268869 creator A5053100242 @default.
• W4309268869 creator A5053124814 @default.
• W4309268869 creator A5060242205 @default.
• W4309268869 creator A5062076815 @default.
• W4309268869 creator A5063301766 @default.
• W4309268869 creator A5063649925 @default.
• W4309268869 creator A5068293508 @default.
• W4309268869 creator A5069737254 @default.
• W4309268869 creator A5071841663 @default.
• W4309268869 creator A5072918409 @default.
• W4309268869 creator A5073477610 @default.
• W4309268869 creator A5073907684 @default.
• W4309268869 creator A5081247376 @default.
• W4309268869 creator A5082564837 @default.
• W4309268869 creator A5083038493 @default.
• W4309268869 creator A5086640521 @default.
• W4309268869 date "2022-11-01" @default.
• W4309268869 modified "2023-10-18" @default.
• W4309268869 title "Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial" @default.
• W4309268869 cites W1978377409 @default.
• W4309268869 cites W2003734726 @default.
• W4309268869 cites W2007584552 @default.
• W4309268869 cites W2013370486 @default.
• W4309268869 cites W2020234719 @default.
• W4309268869 cites W2021954218 @default.
• W4309268869 cites W2025013606 @default.
• W4309268869 cites W2037050131 @default.
• W4309268869 cites W2043779986 @default.
• W4309268869 cites W2044436186 @default.
• W4309268869 cites W2046408556 @default.
• W4309268869 cites W2057346128 @default.
• W4309268869 cites W2068889400 @default.
• W4309268869 cites W2072259475 @default.
• W4309268869 cites W2076003266 @default.
• W4309268869 cites W2102591890 @default.
• W4309268869 cites W2103607521 @default.
• W4309268869 cites W2120113475 @default.
• W4309268869 cites W2128192762 @default.
• W4309268869 cites W2133540202 @default.
• W4309268869 cites W2139260559 @default.
• W4309268869 cites W2148758597 @default.
• W4309268869 cites W2164667231 @default.
• W4309268869 cites W2171811563 @default.
• W4309268869 cites W2318069817 @default.
• W4309268869 cites W2401795134 @default.
• W4309268869 cites W2486629951 @default.
• W4309268869 cites W2518827451 @default.
• W4309268869 cites W2593617117 @default.
• W4309268869 cites W2604776612 @default.
• W4309268869 cites W2613844594 @default.
• W4309268869 cites W2622796688 @default.
• W4309268869 cites W2737964630 @default.
• W4309268869 cites W2739557452 @default.
• W4309268869 cites W2766948867 @default.
• W4309268869 cites W2876010829 @default.
• W4309268869 cites W2899989999 @default.
• W4309268869 cites W2947874495 @default.
• W4309268869 cites W2988984460 @default.
• W4309268869 cites W3145716452 @default.
• W4309268869 doi "https://doi.org/10.1136/bmjopen-2022-063037" @default.
• W4309268869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36396306" @default.
• W4309268869 hasPublicationYear "2022" @default.
• W4309268869 type Work @default.
• W4309268869 citedByCount "3" @default.
• W4309268869 countsByYear W43092688692023 @default.
• W4309268869 crossrefType "journal-article" @default.
• W4309268869 hasAuthorship W4309268869A5001499861 @default.
• W4309268869 hasAuthorship W4309268869A5006399379 @default.
• W4309268869 hasAuthorship W4309268869A5012617779 @default.
• W4309268869 hasAuthorship W4309268869A5015764509 @default.
• W4309268869 hasAuthorship W4309268869A5022440254 @default.
• W4309268869 hasAuthorship W4309268869A5023678967 @default.
• W4309268869 hasAuthorship W4309268869A5024897723 @default.
• W4309268869 hasAuthorship W4309268869A5026876598 @default.
• W4309268869 hasAuthorship W4309268869A5033896752 @default.
• W4309268869 hasAuthorship W4309268869A5036826164 @default.
• W4309268869 hasAuthorship W4309268869A5038580329 @default.
• W4309268869 hasAuthorship W4309268869A5040293585 @default.
• W4309268869 hasAuthorship W4309268869A5042419236 @default.
• W4309268869 hasAuthorship W4309268869A5053100242 @default.
• W4309268869 hasAuthorship W4309268869A5053124814 @default.
• W4309268869 hasAuthorship W4309268869A5060242205 @default.
• W4309268869 hasAuthorship W4309268869A5062076815 @default.

• next